Patents Examined by Ganapathy Krishnan
  • Patent number: 9913854
    Abstract: Provided herein are methods for inducing cell death in a gram positive bacterium and methods for reducing the proliferation of a gram positive bacterium that include contacting a gram positive bacterium with a dye (e.g., an azo dye) and a TarO inhibitor. Also provided are methods of treating a subject having a gram positive bacterial infection that include administering to a subject having a gram positive bacterial infection a dye (e.g., an azo dye) and a TarO inhibitor. Also provided are compositions containing a dye (e.g., an azo dye) and a TarO inhibitor, and kits containing at least one of these compositions.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: March 13, 2018
    Assignee: Massachusetts Eye & Ear Infirmary
    Inventors: Michael S. Gilmore, Takashi Suzuki
  • Patent number: 9907814
    Abstract: A method for treating diastolic heart failure is provided including identifying a subject having diastolic heart failure and administering a therapeutically effective amount of a galectin-3 inhibitor to the subject to at least partially alleviate a symptom of diastolic heart failure.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: March 6, 2018
    Assignee: Henry Ford Health System
    Inventor: Hani N. Sabbah
  • Patent number: 9889204
    Abstract: The disclosure provides, inter alia, polymeric antibiotic compounds such as modified chitosans and methods of use thereof.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: February 13, 2018
    Assignee: The Regents of the University of California
    Inventors: Young Jik Kwon, Julius Edson
  • Patent number: 9879041
    Abstract: The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit ?-secretase.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: January 30, 2018
    Assignees: Victoria Link Limited, University of Liverpool
    Inventors: Peter Charles Tyler, Olga Vladimirovna Zubkova, Jeremy E. Turnbull
  • Patent number: 9846163
    Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: December 19, 2017
    Assignee: Tricol Biomedical, Inc.
    Inventors: Barbara McGrath, Simon McCarthy, Sam Kuhn, Alysha Wold, Michael Stolten, Amanda Bennett
  • Patent number: 9782386
    Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: October 10, 2017
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Mark G. Frattini, Hakim Djaballah, Thomas J. Kelly
  • Patent number: 9765084
    Abstract: A process for the production of a refined dianhydrosugar-containing product is disclosed. The process includes controlled continuous crystallization of the dianhydrosugar-containing product to produce a solution saturated with the dianhydrosugar. The saturated solution is mechanically separated, for example by centrifugation, and the crystalline product is washed. The only solvent used is water. The dianhydrosugar-containing product is upgraded to at least 99.8% purity and recovery is 95% or greater. Recrystallization of the dianhydrosugar of 99.8% purity results in an ultra pure product containing at least 99.99% dianhydrosugar.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: September 19, 2017
    Assignee: Iowa Corn Promotion Board
    Inventors: Charles Guthrie Moyers, James Kermit Withrow, John Leonard Stephens
  • Patent number: 9763973
    Abstract: The present invention provides a or therapeutic agent for HAM, containing pentosan polysulfate or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention also provides an agent for improving a HAM-associated movement disorder, containing pentosan polysulfate or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: September 19, 2017
    Assignees: Nagasaki University, ReqMed Company, Ltd.
    Inventors: Tatsufumi Nakamura, Tadashi Matsumoto
  • Patent number: 9752174
    Abstract: Methods of preparing highly purified steviol glycosides, particularly rebaudiosides A, D and M are described. The methods include utilizing recombinant microorganisms for converting various staring compositions to target steviol glycosides. In addition, novel steviol glycosides reb D2 and reb M2 are disclosed, as are methods of preparing the same. The highly purified rebaudiosides are useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectioneries, bakery products, cookies, and chewing gums.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: September 5, 2017
    Assignees: PureCircle Sdn Bhd, The Coca-Cola Company
    Inventors: Avetik Markosyan, Indra Prakash, Cynthia Bunders, Pankaj Soni, Jarrin Cyrille, Aurélien Badie, Robert ter Halle
  • Patent number: 9738621
    Abstract: Forming multifunctional materials and composites thereof includes contacting a first material having a plurality of oxygen-containing functional groups with a chalcogenide compound, and initiating a chemical reaction between the first material and the chalcogenide compound, thereby replacing oxygen in some of the oxygen-containing functional groups with chalcogen from the chalcogen-containing compound to yield a second material having chalcogen-containing functional groups and oxygen-containing functional groups. The first material is a carbonaceous material or a macromolecular material. A product including the second material is collected and may be processed further to yield a modified product or a composite.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: August 22, 2017
    Assignee: ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Dong-Kyun Seo, Ki-Wan Jeon
  • Patent number: 9738675
    Abstract: A diarylethene compound represented by formula (I) wherein, Sg is a monovalent sugar residue formed by removing one hydroxyl group from a sugar compound or a monovalent protected sugar residue formed by removing one hydroxyl group from a sugar compound in which one or more other hydroxyl groups are protected, and wherein the sugar is selected from the group consisting of a six-membered ring sugar, a five-membered ring sugar, cyclitol, and oligosaccharides containing a six-membered ring sugar, a five-membered ring sugar, or cyclitol; U is —(CH2)n—, —CH2—U?—, or —C(?O)— wherein n is an integer of 1 to 5, U? is a C2-C10 branched alkylene group binding to Ar); and Ar is a group represented by formula (A1) or (A2); wherein, X is S, SO2, NR3 in which R3 is a C1-C3 alkyl group, or O, R is C1-C4 alkyl group, R1 and R2 are independently a C1-C3 alkyl group, a is 0 or 1, b is an integer of 0-3, and * represents a bond with U; Y is a hydrogen atom or a halogen atom; and m is an integer of 3 to 5.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: August 22, 2017
    Assignees: RIKKYO EDUCATIONAL CORPORATION, JOSHO GAKUEN EDUCATIONAL FOUNDATION
    Inventors: Hiroaki Tokiwa, Masahiro Irie, Kiyoshi Ikeda, Tadamune Otsubo
  • Patent number: 9717790
    Abstract: The invention relates to sphingoglycolipid analogues which are useful in treating or preventing diseases and conditions such as those relating to infection, atopic disorders, autoimmune diseases or cancer.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: August 1, 2017
    Assignee: Victoria Link Limited
    Inventors: Regan James Anderson, Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, Karen Anne Johnston, David Samuel Larsen, Gavin Frank Painter
  • Patent number: 9700629
    Abstract: The present invention relates to a composition including S-adenosyl-L-methionine; and at least one kind of additive selected from carboxymethylcellulose, hydroxypropylcellulose, soybean polysaccharide, casein sodium, and zein, in which S-adenosyl-L-methionine is extracted from S-adenosyl-L-methionine-containing cells obtained by culturing a microorganism having an ability to produce SAMe, and the content of the additive in the composition falls within the range of 0.05 to 15 times by mass of S-adenosyl-L-methionine in the composition. The present invention provides a composition containing a high concentration of S-adenosyl-L-methionine, which is useful as a water-soluble physiologically active substance, and being excellent in storage stability and bioabsorbability. The present invention also relates to a molded article formed by using the composition and a method of producing the composition.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: July 11, 2017
    Assignee: MITSUBISHI GAS CHEMICAL COMPANY, INC.
    Inventors: Kentaro Takano, Shinyo Gayama
  • Patent number: 9670245
    Abstract: Provided are several types of ginsenoside polymorphic substances and a method for preparing same. In particular, new crystal form A, crystal form B, crystal form C, crystal form E, crystal form F, crystal form I, crystal form K, crystal form L, crystal form M, crystal form N, and crystal form O are involved.
    Type: Grant
    Filed: April 1, 2013
    Date of Patent: June 6, 2017
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Guobin Ren, Changliang Dai, Jinyao Chen, Feng Chen, Minghui Qi, Wenming Zhu, Minghuang Hong, Hua Bai
  • Patent number: 9662344
    Abstract: A composition for influencing carnitine retention in biological tissue is disclosed. The composition comprises a carnitine substance and an agent to increase sodium potassium ATPase pump activity in the tissue, and/or to increase the activity of a carnitine transport protein, and/or increase blood/plasma insulin concentration.
    Type: Grant
    Filed: March 22, 2004
    Date of Patent: May 30, 2017
    Assignees: The University of Nottingham, Lonza Sales LTD.
    Inventors: Paul Leonard Greenhaff, Dumitru Constantin-Teodosiu
  • Patent number: 9663548
    Abstract: Disclosed herein is 10-?/?-D-Arabinofuranosylundecenes of general Formula (II) or pharmaceutically acceptable salts thereof as anti-mycobacterial agents in vitro; (II) wherein R, R1 and R? are as defined herein in the specification. The present invention also discloses a simple stereoselective synthesis 10-?/?-D-Arabinofuranosylundecenes of Formula (II) to target enzymes involved in the biosynthesis of cell wall of Mycobacterium and thus useful as inhibitors in the Mycobacterium tuberculosis drug development.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: May 30, 2017
    Assignee: Council of Scientific and Industrial Research
    Inventors: Ramana Venkata Chepuri, Dhiman Sarkar, Rahul Shivaji Patil, Sampa Sarkar
  • Patent number: 9662400
    Abstract: The invention provides improved methods for generating biodegradable chitosan compositions, and therapeutic methods of using such compositions to deliver therapeutic agents.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 30, 2017
    Assignee: The University of Memphis Research Foundation
    Inventors: James Keaton Smith, Ashley C. Parker, Jessica A. Jennings, Benjamin T. Reves, Warren O. Haggard
  • Patent number: 9643992
    Abstract: Provided are ginsenoside C-K polymorphic forms and a method for preparing same. The ginsenoside C-K polymorphic forms are crystal form D and crystal form H.
    Type: Grant
    Filed: April 1, 2013
    Date of Patent: May 9, 2017
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Guobin Ren, Changliang Dai, Jinyao Chen, Feng Chen, Minghui Qi, Wenming Zhu, Minghuang Hong, Hua Bai
  • Patent number: 9642948
    Abstract: The invention provides compositions featuring chitosan and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: May 9, 2017
    Assignee: The University of Memphis Research Foundation
    Inventors: Warren O. Haggard, Scott P. Noel, Joel D. Bumgardner
  • Patent number: 9624313
    Abstract: The presently disclosed subject matter concerns a microbial biopolymer comprising fucose in its composition. This biopolymer consists of a polysaccharide comprising fucose, which represents at least 10% of its composition. This fucose-containing polysaccharide also contains non-sugar components, namely, acyl group substituents. This disclosed subject matter also concerns the process for the production of the biopolymer, which is obtained cultivation of the bacterium Enterobacter A47 (DSM 23139), using glycerol or glycerol-rich mixtures as carbon sources. The fucose-containing biopolymer of the presently disclosed subject matter may be used in several industrial applications (e.g. pharmaceutical, cosmetics and agro-food industries) and in the treatment of industrial wastes (e.g. oil and metal recovery).
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: April 18, 2017
    Assignee: 73100-Setenta E Tres Mil E Cem, LDA
    Inventors: Maria D'Ascencao Carvalho Fernandes De Miranda Reis, Rui Manuel Freitas Oliveira, Maria Filomena Andrade De Freitas, Vitor Manuel Delgado Alves